SEARCH
Space and astronomy
Astrophysics
astronomy
Solar System
space missions
man in space
environment and energy
Environmental sciences - the climate crisis
Earth science
environmental issues
energy
transportation
Computing and technology
exact sciences
Computing and robotics
nano-tech
military technology
futurology
Biology and Medicine
Evolution and nature
medicine
Genetics
the brain
Society and history
Science and society
history
The skeptic
Science Fiction
Scientists
Science in Israel
Research and development in Israel
Biotechnology in Israel
Israel in space
the defense industries
Academy and education
Space and astronomy
Astrophysics
astronomy
Solar System
space missions
man in space
environment and energy
Environmental sciences - the climate crisis
Earth science
environmental issues
energy
transportation
Computing and technology
exact sciences
Computing and robotics
nano-tech
military technology
futurology
Biology and Medicine
Evolution and nature
medicine
Genetics
the brain
Society and history
Science and society
history
The skeptic
Science Fiction
Scientists
Science in Israel
Research and development in Israel
Biotechnology in Israel
Israel in space
the defense industries
Academy and education
Hayadan
>
Byline
Byline
Biotechnology Cluster: Pluristem received the approval of the US Registrar for a key patent of the company
The science service
September 20, 2013
No comments
Bioline R.X has completed the recruitment of patients for phase 2b of the clinical trials for a new drug for the treatment of schizophrenia
The science service
May 3, 2009
No comments
Beauline R. X advances a step in approving a drug to treat heart attacks
The science service
January 12, 2009
2 תגובות
Can seaweed mend a broken heart?
Scientific American Israel
September 3, 2008
3 תגובות
Bioline R.X. Announces Initiation of Phase II Human Clinical Trials of BL-1020, a New Drug for the Treatment of Schizophrenia
The science service
July 28, 2007
No comments
Bioline R.X. Launches a program for advanced development
The science service
June 6, 2007
No comments
Bioline R.X. Begins clinical trials to test the effectiveness of BL-1020, an antipsychotic drug for the treatment of schizophrenia
Avi Blizovsky
May 19, 2007
4 תגובות
Beauline R. Ex. Signed a licensing agreement with the Hebrew University and Tel Aviv University for a potential drug to treat inflammatory diseases
Avi Blizovsky
March 23, 2007
5 תגובות
Licensing agreement for Bioline R. Ex. With Bo Gurion University and with the general medicine for anti-inflammatories
The science service
September 18, 2006
No comments
The technological incubators committee approved the establishment of a biotechnological incubator in Jerusalem
Avi Blizovsky
December 2, 2004
No comments